The World Health Organization published its first guidelines on obesity in children and adolescents on 7 October, as two separate documents: one for children up to the age of 9 and one for adolescents aged 10 to 19. Both put structured diet, physical activity and behaviour-change programmes at the centre of care. For children under … Read more
Fewer than a third of commercially insured US adults who started a GLP-1 drug for obesity were still taking it consistently a year later, an analysis of 201,229 claims records has found. About 64% fell into one of three discontinuation patterns: stopping almost immediately, stopping within a few months, or tailing off later in the … Read more
Just under 17% of 10- to 17-year-olds who started a GLP-1 drug were diagnosed with a nutritional deficiency or a related complication within the following year, an analysis of US insurance claims has found. Most of those diagnoses were vitamin D deficiency. Fewer than a quarter of the teenagers saw anyone for nutrition counselling within … Read more
Adolescents with obesity who started semaglutide, liraglutide or tirzepatide were less likely to have a recorded suicide-related event over up to three years than matched adolescents managed with lifestyle intervention, according to an electronic health records study published on 14 September in Diabetes, Obesity and Metabolism. It points away from psychiatric harm in the age … Read more
Between January 2021 and December 2025, Europe’s pharmacovigilance database logged 42,941 adverse-event reports naming liraglutide, semaglutide or tirzepatide as a suspect drug in diabetes or weight management. Of those, 225 involved suicide or self-injury: 141 for semaglutide, 47 for tirzepatide, 37 for liraglutide. A new analysis sets the three against each other and finds such … Read more
A meta-analysis of 60 studies and more than 1.25 million people, published in Drugs on 12 September 2026, gives the fullest picture yet of what GLP-1 drugs do to muscle, bone and joints. The bone finding is reassuring: no measurable effect on bone mineral density, and none on fractures. The muscle finding is the one … Read more
Between a quarter and a third of people who have bariatric surgery regain a significant amount of weight within two to five years, according to the figures cited by the authors of a new review. Their meta-analysis, published in Frontiers in Endocrinology, pulls together what is known about treating that regain with a GLP-1 drug … Read more
Among 216,293 adults with type 2 diabetes, starting an SGLT2 inhibitor was associated with a lower five-year risk of atrial fibrillation than starting a GLP-1 receptor agonist: 4.3% against 4.8%. Starting both classes together came in at 4.2%, statistically indistinguishable from SGLT2 alone. For anyone weighing the two classes with an eye on heart rhythm … Read more